The promoters of the company are Satish Ramanlal Mehta and Sunil Rajanikant Mehta. The registrar of the IPO is Link Intime India Private Limited. The book-running lead managers of the Emcure Pharmaceuticals Limited IPO are Kotak Mahindra Capital Company Limited, Axis Capital Limited, Jefferies India Private Limited, and J. P. Morgan India Private Limited.
The company reported revenue of ₹60,317.16 million in 2023, compared to ₹59,188.60 million in 2022. The profit after tax (PAT) for 2023 was ₹5,618.45 million, down from ₹7,025.56 million in 2022. The company’s peer group includes Dr. Reddy’s Laboratories Limited, Cipla Limited, Alkem Laboratories Limited, Torrent Pharmaceuticals Limited, Mankind Pharma Limited, Abbott India Limited, and J. B. Chemicals & Pharmaceuticals Limited.
Emcure Pharmaceuticals Ltd. is a premier Indian pharmaceutical company dedicated to the development, manufacturing, and global marketing of a diverse range of products, including orals, injectables, and biotherapeutics. Emcure’s strong emphasis on research and development has enabled it to establish a presence in over 70 countries, with a notable foothold in India, Europe, and Canada. The company’s primary therapeutic areas include gynecology, cardiovascular, vitamins, minerals, nutrients, HIV antivirals, blood-related disorders, and oncology/anti-neoplastics.
In the Indian Pharmaceutical Market (IPM), Emcure leads in iron combination products, holds significant positions in gynecology categories such as Progestin, Gonadotropin, and Menstrual disorders, and is the largest company in gynecology and HIV antivirals by Domestic Sales for MAT September 2023 (Source: CRISIL Report). With a robust infrastructure comprising over 350 brands, five R&D centers, and 13 manufacturing facilities across India, Emcure has established a strong market presence both domestically and internationally. The company’s key objective is to continually innovate and provide affordable, high-quality healthcare solutions to people worldwide.
